Pipeline
This is just the beginning
MediSieve has concluded Phase I clinical studies of the Delivery System and is making swift progress in its bead programs. First clinical studies with Beads are expected in 2025.
Pipeline
Discover our current programs and the upcoming ones
Application
Enabling Therapy for AAV Gene Therapies
Adeno-associated virus (AAV) vector-based therapies have revolutionised the field of gene therapy by utilising AAV capsids for targeted in vivo delivery of therapeutic genes. Notably, AAV gene therapies have gained approval as the only in vivo gene therapy treatments in the United States and Europe. While six AAV-based therapies have already been approved, several more are expected to receive approval in the near future. With a staggering 210 ongoing clinical trials, 94 of which have been completed, and 51 of them reaching the efficacy end point, the potential of AAV-based therapies is evident.
These groundbreaking therapies primarily focus on addressing rare genetic disorders. Key indications that have been targeted include Haemophilia A, Haemophilia B, Chloridaemia, Retinitis pigmentosa, Fabry disease, Pompe disease, Hunter Syndrome, Parkinson's disease, Batten Disease, Duchenne Muscular Dystrophy (DMD), and Spinal Muscular Atrophy (SMA). Among the late-stage trials, particular attention is being given to Haemophilia A, Haemophilia B, Retinitis Pigmentosa, and Spinal Muscular Atrophy. The progress in these areas holds immense promise for patients suffering from these debilitating conditions.
However, a significant challenge in utilising AAV-based therapies arises from the prevalence of wild-type AAV infection among individuals. It is estimated that 30-60% of the population possesses AAV neutralising antibodies, which render AAV therapies ineffective (Thomas, 2021). Consequently, nearly half of the patients are ineligible for AAV treatment due to this issue. Moreover, the administration of an AAV therapy triggers the production of AAV-neutralising antibodies, effectively obstructing any future AAV treatments. This problem is not limited to a specific AAV serotype but affects all AAV variants.
Fortunately, MediSieve offers a potential solution to this predicament with its innovative System. By leveraging this technology, AAV neutralising antibodies can be selectively removed from patients, effectively reducing their titer to a level below the critical threshold at which therapies become effective. This breakthrough offers a valuable window of opportunity during which AAV therapies can be successfully performed, enabling patients to benefit from these life-changing treatments.
Application
Enabling Therapy for AAV Gene Therapies
Adeno-associated virus (AAV) vector-based therapies have revolutionised the field of gene therapy by utilising AAV capsids for targeted in vivo delivery of therapeutic genes. Notably, AAV gene therapies have gained approval as the only in vivo gene therapy treatments in the United States and Europe. While six AAV-based therapies have already been approved, several more are expected to receive approval in the near future. With a staggering 210 ongoing clinical trials, 94 of which have been completed, and 51 of them reaching the efficacy end point, the potential of AAV-based therapies is evident.
These groundbreaking therapies primarily focus on addressing rare genetic disorders. Key indications that have been targeted include Haemophilia A, Haemophilia B, Chloridaemia, Retinitis pigmentosa, Fabry disease, Pompe disease, Hunter Syndrome, Parkinson's disease, Batten Disease, Duchenne Muscular Dystrophy (DMD), and Spinal Muscular Atrophy (SMA). Among the late-stage trials, particular attention is being given to Haemophilia A, Haemophilia B, Retinitis Pigmentosa, and Spinal Muscular Atrophy. The progress in these areas holds immense promise for patients suffering from these debilitating conditions.
However, a significant challenge in utilising AAV-based therapies arises from the prevalence of wild-type AAV infection among individuals. It is estimated that 30-60% of the population possesses AAV neutralising antibodies, which render AAV therapies ineffective (Thomas, 2021). Consequently, nearly half of the patients are ineligible for AAV treatment due to this issue. Moreover, the administration of an AAV therapy triggers the production of AAV-neutralising antibodies, effectively obstructing any future AAV treatments. This problem is not limited to a specific AAV serotype but affects all AAV variants.
Fortunately, MediSieve offers a potential solution to this predicament with its innovative System. By leveraging this technology, AAV neutralising antibodies can be selectively removed from patients, effectively reducing their titer to a level below the critical threshold at which therapies become effective. This breakthrough offers a valuable window of opportunity during which AAV therapies can be successfully performed, enabling patients to benefit from these life-changing treatments.
Application
Enabling Therapy for AAV Gene Therapies
Adeno-associated virus (AAV) vector-based therapies have revolutionised the field of gene therapy by utilising AAV capsids for targeted in vivo delivery of therapeutic genes. Notably, AAV gene therapies have gained approval as the only in vivo gene therapy treatments in the United States and Europe. While six AAV-based therapies have already been approved, several more are expected to receive approval in the near future. With a staggering 210 ongoing clinical trials, 94 of which have been completed, and 51 of them reaching the efficacy end point, the potential of AAV-based therapies is evident.
These groundbreaking therapies primarily focus on addressing rare genetic disorders. Key indications that have been targeted include Haemophilia A, Haemophilia B, Chloridaemia, Retinitis pigmentosa, Fabry disease, Pompe disease, Hunter Syndrome, Parkinson's disease, Batten Disease, Duchenne Muscular Dystrophy (DMD), and Spinal Muscular Atrophy (SMA). Among the late-stage trials, particular attention is being given to Haemophilia A, Haemophilia B, Retinitis Pigmentosa, and Spinal Muscular Atrophy. The progress in these areas holds immense promise for patients suffering from these debilitating conditions.
However, a significant challenge in utilising AAV-based therapies arises from the prevalence of wild-type AAV infection among individuals. It is estimated that 30-60% of the population possesses AAV neutralising antibodies, which render AAV therapies ineffective (Thomas, 2021). Consequently, nearly half of the patients are ineligible for AAV treatment due to this issue. Moreover, the administration of an AAV therapy triggers the production of AAV-neutralising antibodies, effectively obstructing any future AAV treatments. This problem is not limited to a specific AAV serotype but affects all AAV variants.
Fortunately, MediSieve offers a potential solution to this predicament with its innovative System. By leveraging this technology, AAV neutralising antibodies can be selectively removed from patients, effectively reducing their titer to a level below the critical threshold at which therapies become effective. This breakthrough offers a valuable window of opportunity during which AAV therapies can be successfully performed, enabling patients to benefit from these life-changing treatments.
Application
Direct Therapy for IL-6 Driven Hyperinflammation
Hyperinflammation or dysregulated immune responses result from an imbalance between pro-inflammatory cytokines, such as IL-6, and anti-inflammatory cytokines, like IL-10. These conditions commonly occur in hospitalised patients, especially those in intensive care units (ICUs). Elevated levels of IL-6 in the bloodstream have been strongly associated with disease progression and outcomes, including prognosis and mortality rates. IL-6's role is particularly prominent in various conditions such as Acute Respiratory Distress Syndrome (ARDS), Acute Pancreatitis, Sepsis, Acute Kidney Injury, Cytokine Release Syndrome, Burn and Trauma, Cardiac Surgery, Pneumonia, and COVID-19.
Standard treatment approaches for these conditions typically involve organ support (such as dialysis and ventilation), fluid management, and appropriate administration of antibiotics. Numerous studies have revealed a correlation between high IL-6 levels upon admission and acute inflammation, as well as a poor prognosis for patients.
MediSieve's product offers a unique selling point by providing the ability to modulate the IL-6 cascade through the physical removal of soluble IL-6 from the blood. This innovative technology holds several key benefits:
1. Improved patient outcomes: By intervening and reducing the severity of hyperinflammatory conditions, this novel approach has the potential to alleviate patient suffering and lower mortality rates.
2. Reduced hospital stay: By mitigating the intensity and severity of hyperinflammatory conditions, the average time spent in ICUs and hospitals can be significantly decreased. This allows patients to be discharged earlier, freeing up vital healthcare resources.
3. Lower treatment costs: Reducing the duration of hospital stays, particularly in ICUs, can lead to substantial cost savings for healthcare systems. By reducing resource utilisation and optimising patient care, the financial burden on both patients and healthcare providers can be reduced.
Application
Direct Therapy for IL-6 Driven Hyperinflammation
Hyperinflammation or dysregulated immune responses result from an imbalance between pro-inflammatory cytokines, such as IL-6, and anti-inflammatory cytokines, like IL-10. These conditions commonly occur in hospitalised patients, especially those in intensive care units (ICUs). Elevated levels of IL-6 in the bloodstream have been strongly associated with disease progression and outcomes, including prognosis and mortality rates. IL-6's role is particularly prominent in various conditions such as Acute Respiratory Distress Syndrome (ARDS), Acute Pancreatitis, Sepsis, Acute Kidney Injury, Cytokine Release Syndrome, Burn and Trauma, Cardiac Surgery, Pneumonia, and COVID-19.
Standard treatment approaches for these conditions typically involve organ support (such as dialysis and ventilation), fluid management, and appropriate administration of antibiotics. Numerous studies have revealed a correlation between high IL-6 levels upon admission and acute inflammation, as well as a poor prognosis for patients.
MediSieve's product offers a unique selling point by providing the ability to modulate the IL-6 cascade through the physical removal of soluble IL-6 from the blood. This innovative technology holds several key benefits:
1. Improved patient outcomes: By intervening and reducing the severity of hyperinflammatory conditions, this novel approach has the potential to alleviate patient suffering and lower mortality rates.
2. Reduced hospital stay: By mitigating the intensity and severity of hyperinflammatory conditions, the average time spent in ICUs and hospitals can be significantly decreased. This allows patients to be discharged earlier, freeing up vital healthcare resources.
3. Lower treatment costs: Reducing the duration of hospital stays, particularly in ICUs, can lead to substantial cost savings for healthcare systems. By reducing resource utilisation and optimising patient care, the financial burden on both patients and healthcare providers can be reduced.
Application
Direct Therapy for IL-6 Driven Hyperinflammation
Hyperinflammation or dysregulated immune responses result from an imbalance between pro-inflammatory cytokines, such as IL-6, and anti-inflammatory cytokines, like IL-10. These conditions commonly occur in hospitalised patients, especially those in intensive care units (ICUs). Elevated levels of IL-6 in the bloodstream have been strongly associated with disease progression and outcomes, including prognosis and mortality rates. IL-6's role is particularly prominent in various conditions such as Acute Respiratory Distress Syndrome (ARDS), Acute Pancreatitis, Sepsis, Acute Kidney Injury, Cytokine Release Syndrome, Burn and Trauma, Cardiac Surgery, Pneumonia, and COVID-19.
Standard treatment approaches for these conditions typically involve organ support (such as dialysis and ventilation), fluid management, and appropriate administration of antibiotics. Numerous studies have revealed a correlation between high IL-6 levels upon admission and acute inflammation, as well as a poor prognosis for patients.
MediSieve's product offers a unique selling point by providing the ability to modulate the IL-6 cascade through the physical removal of soluble IL-6 from the blood. This innovative technology holds several key benefits:
1. Improved patient outcomes: By intervening and reducing the severity of hyperinflammatory conditions, this novel approach has the potential to alleviate patient suffering and lower mortality rates.
2. Reduced hospital stay: By mitigating the intensity and severity of hyperinflammatory conditions, the average time spent in ICUs and hospitals can be significantly decreased. This allows patients to be discharged earlier, freeing up vital healthcare resources.
3. Lower treatment costs: Reducing the duration of hospital stays, particularly in ICUs, can lead to substantial cost savings for healthcare systems. By reducing resource utilisation and optimising patient care, the financial burden on both patients and healthcare providers can be reduced.
Join our newsletter
Sign up to our newsletter
Join our newsletter
Sign up to our newsletter
Join our newsletter
Sign up to our newsletter